Biogen Inc. (Nasdaq: BIIB) announced positive results from the Phase 2 part of the AMETHYST Phase 2/3 study (Part A) of litifilimab in people living with cutaneous lupus erythematosus (CLE).
In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at Week 16, with more litifilimab participants achieving clea ...
As sports betting continues to grow in the U.S., one large aspect of the industry could take a hit under a new bipartisan bill. Introduced by Sens. Adam Schiff (D-Calif.) and John Curtis (R-Utah) on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results